Kimberly Bryant
Family · Defuniak Springs, FLNPI 1235719584
Payments from drug & device makers
Across 138 payments — averaging $17.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$438
- AstraZeneca$391
- GSK$360
- Novo Nordisk$274
- Bayer$197
- Pfizer$162
- plus $556 from 11 others
What the payments were for
- Food & beverage$2,378100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 31 | $438 |
| AstraZeneca | 23 | $391 |
| GSK | 20 | $360 |
| Novo Nordisk | 16 | $274 |
| Bayer | 11 | $197 |
| Pfizer | 9 | $162 |
| Lilly USA, LLC | 9 | $146 |
| Dexcom, Inc. | 5 | $131 |
| Otsuka America Pharmaceutical, Inc. | 3 | $66 |
| Merck | 3 | $46 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $36 |
| Biosense Webster, Inc. | 1 | $35 |
| Grifols USA, LLC | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Novartis | 1 | $19 |
| Medline Industries LP | 1 | $18 |
| Corcept Therapeutics | 1 | $15 |
How this compares
$2,378 in reported general payments places this provider in the 80th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 81 | $90,354 |
| EliquisApixaban | 112 | $86,729 |
| OzempicSemaglutide | 75 | $80,726 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 83 | $77,437 |
| JardianceEmpagliflozin | 89 | $69,739 |
| TrulicityDulaglutide | 36 | $53,761 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 56 | $39,960 |
| JanuviaSitagliptin Phosphate | 42 | $27,263 |
| ZenpepLipase/Protease/Amylase | 11 | $27,081 |
| EntrestoSacubitril/Valsartan | 38 | $25,909 |
| FarxigaDapagliflozin Propanediol | 23 | $24,775 |
| Tresiba Flextouch U-200Insulin Degludec | 35 | $22,824 |
| XareltoRivaroxaban | 26 | $22,104 |
| LinzessLinaclotide | 28 | $16,105 |
| MyrbetriqMirabegron | 29 | $15,898 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $146 | $144,115117 claims |
| PfizerEliquis, Premarin | $162 | $91,592134 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $360 | $83,69594 claims |
| Novo NordiskOzempic | $274 | $80,72675 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $391 | $74,047108 claims |
| MerckJanuvia, Janumet | $46 | $34,18254 claims |
| AbbVieLinzess, Ubrelvy, Namzaric | $438 | $32,39960 claims |
| NovartisEntresto | $19 | $25,90938 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 14,618 family providers in Florida.
Other family in Defuniak Springs
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.